These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32089130)

  • 1. Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction.
    Pilz G; Sakic I; Wipfler P; Kraus J; Haschke-Becher E; Hitzl W; Trinka E; Harrer A
    Fluids Barriers CNS; 2020 Feb; 17(1):7. PubMed ID: 32089130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on "Chemokine CXCL13 in serum, CSF, and blood-CSF barrier function".
    DiSano KD; Gilli F; Pachner AR
    Fluids Barriers CNS; 2021 Feb; 18(1):9. PubMed ID: 33632258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF.
    Harrer C; Otto F; Pilz G; Haschke-Becher E; Trinka E; Hitzl W; Wipfler P; Harrer A
    Fluids Barriers CNS; 2021 Aug; 18(1):40. PubMed ID: 34446066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation.
    Hytönen J; Kortela E; Waris M; Puustinen J; Salo J; Oksi J
    J Neuroinflammation; 2014 Jun; 11():103. PubMed ID: 24920219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis.
    Rupprecht TA; Plate A; Adam M; Wick M; Kastenbauer S; Schmidt C; Klein M; Pfister HW; Koedel U
    J Neuroinflammation; 2009 Dec; 6():42. PubMed ID: 20042073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset.
    Puthenparampil M; Federle L; Miante S; Zito A; Toffanin E; Ruggero S; Ermani M; Pravato S; Poggiali D; Perini P; Rinaldi F; Gallo P
    J Neuroinflammation; 2017 Jan; 14(1):11. PubMed ID: 28095856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL13 and CXCL12 in central nervous system lymphoma patients.
    Fischer L; Korfel A; Pfeiffer S; Kiewe P; Volk HD; Cakiroglu H; Widmann T; Thiel E
    Clin Cancer Res; 2009 Oct; 15(19):5968-73. PubMed ID: 19773382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response.
    Leypoldt F; Höftberger R; Titulaer MJ; Armangue T; Gresa-Arribas N; Jahn H; Rostásy K; Schlumberger W; Meyer T; Wandinger KP; Rosenfeld MR; Graus F; Dalmau J
    JAMA Neurol; 2015 Feb; 72(2):180-6. PubMed ID: 25436993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of chemokines CCL2, CXCL8, 10 and 13 and interleukin 6 in the pediatric cohort for the recognition of neuroinflammation and in the context of traditional cerebrospinal fluid neuroinflammatory biomarkers.
    Liba Z; Nohejlova H; Capek V; Krsek P; Sediva A; Kayserova J
    PLoS One; 2019; 14(7):e0219987. PubMed ID: 31356620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid CXCL13 as a diagnostic marker of neuroborreliosis in children: a retrospective case-control study.
    Remy MM; Schöbi N; Kottanattu L; Pfister S; Duppenthaler A; Suter-Riniker F
    J Neuroinflammation; 2017 Aug; 14(1):173. PubMed ID: 28859668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.
    Kowarik MC; Cepok S; Sellner J; Grummel V; Weber MS; Korn T; Berthele A; Hemmer B
    J Neuroinflammation; 2012 May; 9():93. PubMed ID: 22591862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.
    Sellebjerg F; Börnsen L; Khademi M; Krakauer M; Olsson T; Frederiksen JL; Sørensen PS
    Neurology; 2009 Dec; 73(23):2003-10. PubMed ID: 19996075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of CXCL10, CXCL11, CXCL12 and CXCL13 chemokines in serum and cerebrospinal fluid in patients with tick borne encephalitis (TBE).
    Zajkowska J; Moniuszko-Malinowska A; Pancewicz SA; Muszyńska-Mazur A; Kondrusik M; Grygorczuk S; Swierzbińska-Pijanowska R; Dunaj J; Czupryna P
    Adv Med Sci; 2011; 56(2):311-7. PubMed ID: 22008312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study.
    Pilz G; Wipfler P; Otto F; Hitzl W; Afazel S; Haschke-Becher E; Trinka E; Harrer A
    J Neuroinflammation; 2019 Jan; 16(1):13. PubMed ID: 30660201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection.
    Bremell D; Mattsson N; Edsbagge M; Blennow K; Andreasson U; Wikkelsö C; Zetterberg H; Hagberg L
    BMC Neurol; 2013 Jan; 13():2. PubMed ID: 23294475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.
    Bielekova B; Komori M; Xu Q; Reich DS; Wu T
    PLoS One; 2012; 7(11):e48370. PubMed ID: 23226202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL13 chemokine in pediatric and adult neuroborreliosis.
    Wutte N; Berghold A; Löffler S; Zenz W; Daghofer E; Krainberger I; Kleinert G; Aberer E
    Acta Neurol Scand; 2011 Nov; 124(5):321-8. PubMed ID: 21320077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis.
    Marra CM; Tantalo LC; Sahi SK; Maxwell CL; Lukehart SA
    Sex Transm Dis; 2010 May; 37(5):283-7. PubMed ID: 20393380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient.
    Castellazzi M; Morotti A; Tamborino C; Alessi F; Pilotto S; Baldi E; Caniatti LM; Trentini A; Casetta I; Granieri E; Pugliatti M; Fainardi E; Bellini T
    Fluids Barriers CNS; 2020 Feb; 17(1):14. PubMed ID: 32024544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.